These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19819909)

  • 1. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis.
    Pérez-Molina JA; Pérez-Ayala A; Moreno S; Fernández-González MC; Zamora J; López-Velez R
    J Antimicrob Chemother; 2009 Dec; 64(6):1139-47. PubMed ID: 19819909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country.
    Murcia L; Carrilero B; Muñoz MJ; Iborra MA; Segovia M
    J Antimicrob Chemother; 2010 Aug; 65(8):1759-64. PubMed ID: 20542903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Profile of Benznidazole in the Treatment of Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review with Meta-Analysis.
    Crespillo-Andújar C; Venanzi-Rullo E; López-Vélez R; Monge-Maillo B; Norman F; López-Polín A; Pérez-Molina JA
    Drug Saf; 2018 Nov; 41(11):1035-1048. PubMed ID: 30006773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis.
    Crespillo-Andújar C; Comeche B; Hamer DH; Arevalo-Rodriguez I; Alvarez-Díaz N; Zamora J; Pérez-Molina JA
    PLoS Negl Trop Dis; 2022 May; 16(5):e0010386. PubMed ID: 35576215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal follow up of serological response in children treated for Chagas disease.
    Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression and Chagas disease; experience from a non-endemic country.
    Salvador F; Sánchez-Montalvá A; Valerio L; Serre N; Roure S; Treviño B; Pou D; Sulleiro E; Bocanegra C; Molina I
    Clin Microbiol Infect; 2015 Sep; 21(9):854-60. PubMed ID: 26055418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of benznidazole use in the treatment of chronic Chagas' disease.
    Hasslocher-Moreno AM; do Brasil PE; de Sousa AS; Xavier SS; Chambela MC; Sperandio da Silva GM
    J Antimicrob Chemother; 2012 May; 67(5):1261-6. PubMed ID: 22331592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain.
    Ramos JM; Torrús D; Amador C; Jover F; Pérez-Chacón F; Ponce Y; Arjona FJ; Caro E; Martínez-Peinado C; Gallegos I; Cuadrado JM; Tello A; Gutiérrez F
    Pathog Glob Health; 2012 Oct; 106(6):340-5. PubMed ID: 23182138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
    Morillo CA; Marin-Neto JA; Avezum A; Sosa-Estani S; Rassi A; Rosas F; Villena E; Quiroz R; Bonilla R; Britto C; Guhl F; Velazquez E; Bonilla L; Meeks B; Rao-Melacini P; Pogue J; Mattos A; Lazdins J; Rassi A; Connolly SJ; Yusuf S;
    N Engl J Med; 2015 Oct; 373(14):1295-306. PubMed ID: 26323937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease.
    Laucella SA; Segura EL; Riarte A; Sosa ES
    Clin Exp Immunol; 1999 Dec; 118(3):423-7. PubMed ID: 10594562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
    Rumi MM; Pérez Brandán C; Gil JF; D'Amato AM; Ragone PG; Lauthier JJ; Tomasini N; Cimino RO; Orellana V; Lacunza CD; Nasser JR; Basombrío MA; Diosque P
    Acta Trop; 2013 Oct; 128(1):130-6. PubMed ID: 23880286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study.
    Álvarez MG; Vigliano C; Lococo B; Bertocchi G; Viotti R
    Acta Trop; 2017 Oct; 174():149-152. PubMed ID: 28720492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment.
    Aldasoro E; Posada E; Requena-Méndez A; Calvo-Cano A; Serret N; Casellas A; Sanz S; Soy D; Pinazo MJ; Gascon J
    J Antimicrob Chemother; 2018 Apr; 73(4):1060-1067. PubMed ID: 29351667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).
    Marin-Neto JA; Rassi A; Morillo CA; Avezum A; Connolly SJ; Sosa-Estani S; Rosas F; Yusuf S;
    Am Heart J; 2008 Jul; 156(1):37-43. PubMed ID: 18585495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
    Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Silvestre de Sousa A; Sangenis LHC; Brasil PEAAD; Mejía RA; Fux CP; Cubides JC; Saraiva RM; Brum-Soares LM
    J Antimicrob Chemother; 2017 Sep; 72(9):2596-2601. PubMed ID: 28645201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.
    Fernández-Villegas A; Pinazo MJ; Marañón C; Thomas MC; Posada E; Carrilero B; Segovia M; Gascon J; López MC
    BMC Infect Dis; 2011 Jul; 11():206. PubMed ID: 21801456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.